The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy
Open accessAbstract
Purpose: The phosphoinositide-3-kinase (PI3K), phosphatase and tensin homolog (PTEN), v-akt murine thymoma viral oncogene homolog (AKT), and mammalian target of rapamycin (mTOR) signaling pathway has been implicated in resistance to several chemotherapeutic agents. In this retrospective study, we determined whether common genetic variations in this pathway are associated with clinical outcomes in esophageal cancer patients with adenocarcinoma or squamous cell carcinoma who have undergone chemoradiotherapy and surgery. Patients and Methods: Sixteen tagging single nucleotide polymorphisms (SNPs) in PIK3CA, PTEN, AKT1, AKT2, and FRAP1 (encoding mTOR) were genotyped in these patients and analyzed for associations with response to therapy, survival, and recurrence. Results: We observed an increased recurrence risk with genetic variations in AKT1 and AKT2 (hazard ratio [HR], 2.21; 95% CI, 1.06 to 4.60; and HR, 3.30; 95% CI, 1.64 to 6.66, respectively). This effect was magnified with an increasing number of AKT adverse genotypes. In contrast, a predictable protective effect by PTEN genetic variants on recurrence was evident. Survival tree analysis identified higher-order interactions that resulted in variation in recurrence-free survival from 12 to 42 months, depending on the combination of SNPs. Genetic variations in AKT1, AKT2, and FRAP1 were associated with survival. Patients homozygous for either of the FRAP1 SNPs assayed had a more than three-fold increased risk of death. Two genes—AKT2 and FRAP1—were associated with a poor treatment response, while a better response was associated with heterozygosity for AKT1:rs3803304 (odds ratio, 0.50; 95% CI, 0.25 to 0.99). Conclusion: These results suggest that common genetic variations in this pathway modulate clinical outcomes in patients who undergo chemoradiotherapy. With further validation, these results may be used to build a model of individualized therapy for the selection of the optimal chemotherapeutic regimen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
A haplotype map of the human genome
The International HapMap Consortium (2005) · Nature · doi:10.1038/nature04226 · Cited by 5,858
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Tee, A. R., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C., & Blenis, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202476899 · Cited by 827 · cited 1×
“AKT phosphorylation of TSC2 inhibits the function of this complex, allowing for the activation of mTOR.(30) Genetic variation in these four genes—PDK1, PDK2, TSC1, and TSC2—may contribute to additional variation in clinical outcome, especially in combination with genetically altered AKT.”
Background
Cited by
Protein post-translational modifications and regulation of pluripotency in human stem cells
Wang, Y.-C., Peterson, S. E., & Loring, J. F. (2014) · Cell Research · doi:10.1038/cr.2013.151 · Cited by 395
The Crosstalk of mTOR/S6K1 and Hedgehog Pathways
Wang, Y., Ding, Q., Yen, C.-J., Xia, W., Izzo, J. G., Lang, J.-Y., Li, C.-W., Hsu, J. L., Miller, S. A., Wang, X., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.028 · Cited by 346
Self-citationLi, W.-Q., Hu, N., Wang, Z., Yu, K., Su, H., Wang, L., Wang, C., Chanock, S. J., Burdett, L., Ding, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068999 · Cited by 24
Metadata
- Authors
- Hildebrandt, M. A. T., Yang, H., Hung, M.-C., Izzo, J. G., Huang, M., Lin, J., Ajani, J. A., & Wu, X.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-20
- Volume
- 27
- Issue
- 6
- Pages
- 857-871
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2155838479
- Cited by
- 162
- References
- 4
- FWCI
- 16.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy. https://app.cochat.ai/papers/10.1200/jco.2008.17.6297
- The paper
- Hildebrandt, M. A. T., Yang, H., Hung, M.-C., Izzo, J. G., Huang, M., Lin, J., Ajani, J. A., & Wu, X. (2009). Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.17.6297
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.